Ascletis' ASC36_35FDC Shows Superior Weight Loss in Preclinical…

Event summary

ASC36_35FDC demonstrated 24.8% weight loss in DIO rat model, outperforming competitors by 98% and 47% respectively.
Preclinical data presented at EASD 2026 showed excellent formulation stability with no fibrotic aggregation.
ASC36_35FDC exhibited half-lives of 781 hours (ASC36) and 721 hours (ASC35), supporting once-monthly to once-quarterly dosing.
Oral tablet formulation of ASC36_35FDC developed for once-weekly administration.

The big picture

Ascletis' ASC36_35FDC represents a strategic push into the competitive weight-loss market with a differentiated dosing profile. The combination of amylin and GLP-1R/GIPR agonism aims to leverage synergistic effects for superior weight reduction. The ultra-long-acting formulation could address patient adherence challenges, a key barrier in chronic weight management therapies. The company's proprietary AI-assisted drug discovery and ultra-long-acting platforms position it to develop best-in-class metabolic disease treatments.

What we're watching

Clinical Translation: Whether preclinical results will translate to human trials with similar efficacy and safety profiles.
Regulatory Pathway: The pace at which Ascletis can advance ASC36_35FDC through clinical stages and secure regulatory approvals.
Market Positioning: How ASC36_35FDC will compete against existing and emerging weight-loss therapies in the chronic weight management space.